Home LiteratureArticle Details
PMID: 8692823 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency.

Emiliani S, Van Lint C, Fischle W, Paras P, Ott M, Brady J, Verdin E

Abstract

Study of the mechanism of HIV-1 postintegration latency in the ACH2 cell line demonstrates that these cells failed to increase HIV-1 production following treatment with exogenous Tat. Reasoning that the defect in ACH2 cells involves the Tat response, we analyzed the sequence of tat cDNA and Tat responsive element (TAR) from the virus integrated in ACH2. Tat cDNA sequence is closely related to that of HIV LAI, and the encoded protein is fully functional in terms of long terminal repeat (LTR) transactivation. Cloning of a region corresponding to the 5'-LTR from ACH2, however, identified a point mutation (C37 -> T) in TAR. This mutation impaired Tat responsiveness of the LTR in transient transfection assays, and the measured defect was complemented in cells that had been treated with tetradecanoyl phorbol acetate or tumor necrosis factor type alpha (TNF-alpha). A compensatory mutation in TAR (G28 -> A), designed to reestablish base pairing in the TAR hairpin, restored wild-type Tat responsiveness. When the (C37 -> T) mutation was introduced in an infectious clone of HIV-1, no viral production was measured in the absence of TNF-alpha, whereas full complementation was observed when the infection was conducted in the presence of TNF-alpha or when a compensatory mutation (G28 -> A) was introduced into TAR. These experiments identify a novel mutation associated with HIV-1 latency and suggest that alterations in the Tat-TAR axis can be a crucial determinant of the latent phenotype in infected individuals.

MeSH Terms
Base Sequence DNA Primers Gene Products, tat/genetics HIV Long Terminal Repeat HIV-1/genetics,pathogenicity,physiology Molecular Sequence Data Mutagenesis, Site-Directed Phenotype Point Mutation Proviruses/genetics,pathogenicity,physiology Transfection Virus Latency/genetics Virus Replication/genetics tat Gene Products, Human Immunodeficiency Virus
Chemicals
DNA Primers Gene Products, tat tat Gene Products, Human Immunodeficiency Virus
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Emiliani S
The Picower Institute for Medical Research, Manhasset, NY 11030, USA.
Van Lint C
Fischle W
Paras P
Ott M
Brady J
Verdin E
References (40)
40 references, click to expand
  1. Two distinct nuclear transcription factors recognize loop and bulge residues of the HIV-1 TAR RNA hairpin.
    Genes Dev. 1991 Dec;5(12B):2508-20 PMID: 1752441
  2. DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1.
    J Virol. 1991 Dec;65(12):6790-9 PMID: 1942252
  3. Cellular latency of human immunodeficiency virus type 1.
    Curr Opin Immunol. 1992 Aug;4(4):475-80 PMID: 1388848
  4. Electroporation of viral transactivator proteins into lymphocyte suspension cells.
    Nucleic Acids Res. 1992 Sep 11;20(17):4673-4 PMID: 1408778
  5. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.
    Nature. 1993 Mar 25;362(6418):355-8 PMID: 8455722
  6. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.
    Nature. 1993 Mar 25;362(6418):359-62 PMID: 8096068
  7. Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in situ hybridization and flow cytometry.
    Science. 1993 May 14;260(5110):976-9 PMID: 8493534
  8. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.
    EMBO J. 1993 Aug;12(8):3249-59 PMID: 8344262
  9. HIV-1 latency due to the site of proviral integration.
    Virology. 1993 Oct;196(2):849-54 PMID: 8372452
  10. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses.
    J Virol. 1994 Feb;68(2):654-60 PMID: 7507183
  11. Analysis of Tat function in human immunodeficiency virus type 1-infected low-level-expression cell lines U1 and ACH-2.
    J Virol. 1994 Mar;68(3):1993-7 PMID: 8107261
  12. Tat and rev differentially affect restricted replication of human immunodeficiency virus type 1 in various cells.
    Virology. 1994 Mar;199(2):474-8 PMID: 8122376
  13. A transcriptional regulatory element is associated with a nuclease-hypersensitive site in the pol gene of human immunodeficiency virus type 1.
    J Virol. 1994 Apr;68(4):2632-48 PMID: 8139041
  14. Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency.
    J Virol. 1994 Apr;68(4):2726-30 PMID: 7511177
  15. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts.
    Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3862-6 PMID: 8171003
  16. Differential growth kinetics are exhibited by human immunodeficiency virus type 1 TAR mutants.
    J Virol. 1994 Sep;68(9):5899-910 PMID: 8057469
  17. Characterization of a "kissing" hairpin complex derived from the human immunodeficiency virus genome.
    Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8705-9 PMID: 8078946
  18. Viral latency in HIV disease.
    Cell. 1995 Jul 28;82(2):183-8 PMID: 7628009
  19. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).
    Science. 1985 Jul 5;229(4708):69-73 PMID: 2990040
  20. Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization.
    Proc Natl Acad Sci U S A. 1986 Feb;83(3):772-6 PMID: 3003749
  21. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.
    J Virol. 1986 Aug;59(2):284-91 PMID: 3016298
  22. Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein.
    Cell. 1987 Feb 27;48(4):691-701 PMID: 3643816
  23. Cellular uptake of the tat protein from human immunodeficiency virus.
    Cell. 1988 Dec 23;55(6):1189-93 PMID: 2849510
  24. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone.
    J Immunol. 1989 Jan 15;142(2):431-8 PMID: 2463307
  25. Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections.
    Proc Natl Acad Sci U S A. 1989 Jan;86(2):675-9 PMID: 2492110
  26. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone.
    Proc Natl Acad Sci U S A. 1989 Apr;86(7):2365-8 PMID: 2784570
  27. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4.
    Science. 1989 Jul 21;245(4915):305-8 PMID: 2665081
  28. Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression.
    Cell. 1989 Jul 14;58(1):215-23 PMID: 2752420
  29. Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals.
    J Virol. 1989 Nov;63(11):4626-31 PMID: 2795714
  30. The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity.
    J Virol. 1989 Nov;63(11):4919-24 PMID: 2795721
  31. Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression.
    Proc Natl Acad Sci U S A. 1990 Jan;87(2):782-5 PMID: 2300561
  32. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency.
    Cell. 1990 Jun 29;61(7):1271-6 PMID: 2364429
  33. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat.
    Proc Natl Acad Sci U S A. 1990 Jul;87(13):5079-83 PMID: 2195547
  34. A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation.
    Genes Dev. 1990 Aug;4(8):1365-73 PMID: 2227414
  35. HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure.
    EMBO J. 1990 Dec;9(12):4145-53 PMID: 2249668
  36. Analysis of arginine-rich peptides from the HIV Tat protein reveals unusual features of RNA-protein recognition.
    Genes Dev. 1991 Feb;5(2):201-10 PMID: 1899841
  37. Endocytosis and targeting of exogenous HIV-1 Tat protein.
    EMBO J. 1991 Jul;10(7):1733-9 PMID: 2050110
  38. Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types.
    J Virol. 1991 Aug;65(8):4350-8 PMID: 2072454
  39. tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185.
    Genes Dev. 1991 Nov;5(11):2128-40 PMID: 1936997
  40. Absence of selection of HIV-1 variants in vivo based on transcription/transactivation during progression to AIDS.
    Virology. 1992 Jun;188(2):811-8 PMID: 1350126
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
1996-06-25
Pages
6377-81
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC39030
Subset
IM
Grants
NIGMS NIH HHS · GM51671-01A1 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]